UBS has reduced its short position in China Biopharmaceuticals to 1.33%.

As of May 2, 2025, UBS Group has reduced its non-net short position in China Biopharmaceutical Limited by 8.22% to 153.3 million shares, representing 1.33% of the company's stock.